Imagen de Portada

MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Monika Tomaszewska‐Kiecana, Elisabete Carapuça, Amalia Florez‐Igual, Javier Queiruga‐Parada
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Clinical and Translational Science
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects
por: Xianglei Gao, et al.
Publicado: (2024)

Safety, pharmacokinetics, and food effect of sudapyridine (WX‐081), a novel anti‐tuberculosis candidate in healthy Chinese subjects
por: Chengyin Yu, et al.
Publicado: (2024)

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
por: Kyoko Miyamoto, et al.
Publicado: (2024)

Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
por: Akira Tanaka, et al.
Publicado: (2024)

Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants
por: Ye Chan Park, et al.
Publicado: (2024)

Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study
por: Na Li, et al.
Publicado: (2024)

Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
por: Byung Hak Jin, et al.
Publicado: (2024)

Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects
por: Rajinder Bhardwaj, et al.
Publicado: (2024)

Pioglitazone‐induced alterations of purine metabolism in healthy male subjects
por: Jihyun Kang, et al.
Publicado: (2024)

Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects
por: Heejae Won, et al.
Publicado: (2024)

Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects
por: Jingcheng Chen, et al.
Publicado: (2024)

Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG
por: Jean‐Pierre Bellier, et al.
Publicado: (2024)

Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”
Publicado: (2024)

A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants
por: Shichang Miao, et al.
Publicado: (2024)

Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
por: Jia‐yu Zhang, et al.
Publicado: (2024)

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
por: Xiaomeng Mao, et al.
Publicado: (2024)

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants
por: Ana Liza Andresan Sun, et al.
Publicado: (2024)

Systemic lupus erythematosus extends beyond a type I interferonopathy, as demonstrated by NET‐activated monocytes
por: Xiaolin Cao, et al.
Publicado: (2026)

Efficacy and safety of CT‐P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16‐week follow‐up study
por: Clive Grattan, et al.
Publicado: (2025)

A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers
por: Marie‐José Cabanis, et al.
Publicado: (2024)

Randomized, placebo‐controlled, double‐blind phase I trial of co‐administered pyronaridine and piperaquine in healthy adults of sub‐Saharan origin
por: Andrea Kuemmerle, et al.
Publicado: (2024)

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies
por: Juanjuan Jiang, et al.
Publicado: (2024)

Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
por: William K. Schmidt, et al.
Publicado: (2024)

A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males
por: Emmanuel Biver, et al.
Publicado: (2026)

Pooled analysis of routine safety parameters observed in healthy participants at baseline and following placebo administration in early phase clinical studies
por: Kelly E. Duncan, et al.
Publicado: (2024)

Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study
por: Andrew Gewitz, et al.
Publicado: (2024)

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
por: Guihong Yang, et al.
Publicado: (2024)

AdjuvareDB: A comprehensive database for candidate adjuvant compendium in clinic
por: Dekang Ren, et al.
Publicado: (2024)

Correction to “Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers”
Publicado: (2024)

Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
por: Tianxing Liu, et al.
Publicado: (2024)

Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males
por: Heejae Won, et al.
Publicado: (2024)

No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults
por: Rajinder Bhardwaj, et al.
Publicado: (2024)

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist
por: Yun Liu, et al.
Publicado: (2024)

Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis
por: Nabila Ibnou Zekri Lassout, et al.
Publicado: (2024)

Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
por: Huijun Chen, et al.
Publicado: (2024)

Questions in self‐selection studies used in consumer research for nonprescription drug candidates: Limitations and recommendations
por: Eric P. Brass, et al.
Publicado: (2024)

Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
por: Hengbang Wang, et al.
Publicado: (2024)

A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
por: Michael B. Lilly, et al.
Publicado: (2024)

Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population
por: Simon Dagenais, et al.
Publicado: (2024)

Case of a 96‐year‐old woman with tilt of the subjective vertical axis
por: Markus A. Hobert, et al.
Publicado: (2025)